Insulin-like growth factor-I gene delivery to astrocytes reduces their inflammatory response to lipopolysaccharide by Bellini, María José et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Insulin-like growth factor-I gene delivery to astrocytes reduces their
inflammatory response to lipopolysaccharide
Journal of Neuroinflammation 2011, 8:21 doi:10.1186/1742-2094-8-21
Maria J Bellini (mariajosebellini@yahoo.com)
Claudia B Herenu (c_herenu@yahoo.com)
Rodolfo G Goya (goya@isis.unlp.edu.ar)
Luis M Garcia-Segura (lmgs@cajal.csic.es)
ISSN 1742-2094
Article type Research
Submission date 20 September 2010
Acceptance date 3 March 2011
Publication date 3 March 2011
Article URL http://www.jneuroinflammation.com/content/8/1/21
This peer-reviewed article was published immediately upon acceptance. It can be downloaded,
printed and distributed freely for any purposes (see copyright notice below).
Articles in JNI are listed in PubMed and archived at PubMed Central.
For information about publishing your research in JNI or any BioMed Central journal, go to
http://www.jneuroinflammation.com/info/instructions/
For information about other BioMed Central publications go to
http://www.biomedcentral.com/
Journal of Neuroinflammation
© 2011 Bellini et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  1
Insulin-like growth factor-I gene delivery to astrocytes reduces their 
inflammatory response to lipopolysaccharide 
 
Maria J Bellini1, Claudia B Hereñú2, Rodolfo G Goya2, Luis M Garcia-Segura1§ 
 
1Instituto Cajal, CSIC, Madrid, Spain 
2INIBIOLP-Histology B, School of Medicine, Faculty of Medicine, University of 
La Plata, CC 455, 1900, La Plata, Argentina 
 
 
§ Corresponding author 
 
Email addresses: 
MJB: mariajosebellini@yahoo.com 
CBH: c_herenu@yahoo.com 
RGG: goya@isis.unlp.edu.ar 
LMGS: lmgs@cajal.csic.es 
  2
Abstract 
Background: Insulin-like growth factor-I (IGF-I) exerts neuroprotective actions 
in the central nervous system that are mediated at least in part by control of 
activation of astrocytes. In this study we have assessed the efficacy of 
exogenous IGF-I and IGF-I gene therapy in reducing the inflammatory response 
of astrocytes from cerebral cortex.  
Methods: An adenoviral vector harboring the rat IGF-I gene and a control 
adenoviral vector harboring a hybrid gene encoding the herpes simplex virus 
type 1 thymidine kinase fused to Aequorea victoria enhanced green fluorescent 
protein were used in this study. Primary astrocytes from mice cerebral cortex 
were incubated for 24 h or 72 h with vehicle, IGF-I, the IGF-I adenoviral vector, 
or control vector; and exposed to bacterial lipopolysaccharide to induce an 
inflammatory response. IGF-I levels were measured by radioimmunoassay. 
Levels of interleukin 6, tumor necrosis factor-α, interleukin-1β and toll-like 
receptor 4 mRNA were assessed by quantitative real-time polymerase chain 
reaction. Levels of IGF-I receptor and IGF binding proteins 2 and 3 were 
assessed by western blotting. The subcellular distribution of nuclear factor κB 
(p65) was assessed by immunocytochemistry. Statistical significance was 
assessed by one way analysis of variance followed by the Bonferroni pot hoc 
test. 
Results: IGF-I gene therapy increased IGF-I levels without affecting IGF-I 
receptors or IGF binding proteins. Exogenous IGF-I, and IGF-I gene therapy, 
decreased expression of toll-like receptor 4 and counteracted the 
lipopolysaccharide-induced inflammatory response of astrocytes. In addition, 
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IGF-I gene therapy decreased lipopolysaccharide-induced translocation of 
nuclear factor κB (p65) to the cell nucleus.  
Conclusion: These findings demonstrate efficacy of exogenous IGF-I and of 
IGF-I gene therapy in reducing the inflammatory response of astrocytes. IGF-I 
gene therapy may represent a new approach to reduce inflammatory reactions 
in glial cells.  
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Background 
As a source of growth factors and of immunologically relevant cytokines and 
chemokines, astrocytes play a pivotal role in the pathophysiology of 
neurodegenerative diseases [1-3] and in the type and extent of central nervous 
system immune and inflammatory responses [4]. These responses may 
promote tissue repair and contribute to recovery of homeostasis under acute 
neurodegerative conditions. However, sustained inflammatory responses of 
astrocytes in chronic neurodegenerative diseases may enhance tissue damage 
through amplification of brain inflammation and consequent neuronal injury [4-
8]. Therefore, to limit neuronal cell death under chronic neurodegenerative 
conditions, it is important to develop tools to control brain inflammatory 
reactions.  
 
IGF-I is locally produced in the nervous system and it is also actively 
transported to the brain from plasma through the choroid plexus [9,10]. IGF-I 
has pleiotropic actions in nervous tissue, influencing neuronal development, 
synaptic plasticity, neuroendocrine regulation, adult neurogenesis and cognition 
[11-14]. IGF-I is also a potent neuroprotective molecule [10,13,15,16] exerting 
this function in part by reducing brain inflammation [17,18] and reactive 
astrocytosis [19]. In response to neurodegenerative conditions, astrocytes 
express IGF-I, probably as an endogenous neuroprotective and anti-
inflammatory mechanism [20-23]. Consequently, the development of 
methodologies to increase IGF-I production by glial cells is a logical approach to 
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implement anti-inflammatory IGF-I-based therapeutic strategies for 
neurodegenerative diseases.  
 
We have recently constructed a recombinant adenovirus vector harboring the 
rat IGF-I gene [24,25]. Using this vector we have shown efficacy of IGF-I gene 
therapy to increase IGF-I levels in cerebrospinal fluid and to reduce neuronal 
damage in vivo [24,25]. In the present study we have explored whether 
exogenous IGF-I and IGF-I gene therapy regulate the inflammatory response of 
astrocytes.  
 
Methods 
Adenoviral vectors 
A recombinant adenovirus (RAd) vector harboring the rat IGF-I gene (RAd-IGF-
I) was constructed as previously described [24] using a variant of the two-
plasmid method [26] The cDNA coding for the rat IGF-I gene (kindly donated by 
Dr. Peter Rotwein, Department of Biochemistry and Molecular Biology, Oregon 
Health & Science University, Portland, OR), obtained from the mRNA for the 
IGF-Ib precursor form [27], was placed under the control of the mCMV promoter 
in order to construct the genome of the desired RAd-IGF-I (Fig. 1). The newly 
generated RAd was rescued from human embryo kidney 293 (HEK293) cell 
lysates and plaque purified. It was further purified by ultracentrifugation in a 
CsCl gradient. Final virus stocks were titrated by a serial dilution plaque assay. 
 
A control RAd vector (RAd-TK/GFP) harboring a hybrid gene encoding the 
herpes simplex virus type 1 (HSV-1) thymidine kinase fused to Aequorea 
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victoria enhanced green fluorescent protein (a kind gift from Dr. Jacques 
Galipeau, McGill University, Montreal, Canada) was constructed following the 
general procedures outlined above (Fig. 1). The corresponding gene product, 
fusion protein TK/GFP, emits green fluorescence with high intensity when 
excited with 470-nm wideband light [28]. This hybrid gene is also driven by the 
mCMV promoter. The vector was expanded in 293 cells and purified and titrated 
as indicated above. 
 
Astrocyte cultures 
Astrocyte cultures were prepared by mechanical dissociation of cerebral cortex 
from newborn CD1 mice [29]. Experimental procedures were approved by our 
Institutional Animal Use and Care Committee (Spanish National Research 
Council Animal Experimentation Committee). Cell culture reagents were 
purchased from Invitrogen (Paisley, UK). The cortex was isolated under a 
dissecting microscope and cleaned of choroid plexus and meninges. Cell 
suspensions were filtered through a 70-µm nylon cell strainer into phenol red 
free Dulbecco´s modified Eagle medium (DMEM) containing 10% fetal calf 
serum and 1% penicillin–streptomycin. After centrifugation, cells were cultured 
in 75-cm2 tissue culture flasks at 37ºC and 5% CO2. The medium was changed 
after 4 days in culture and subsequently two times a week for the entire culture 
period. Cellular confluence was observed 10 days after plating, producing 
around 4.3x106 cells per flask, showing a polygonal flat morphology. Enriched 
astrocyte cultures (90-95% of GFAP immunoreactive cells) were obtained after 
overnight shaking at 37ºC a 280 rpm in a table top shaker (Thermo Forma, 
Marietta, OH) to minimize oligodendrocyte and microglia contamination. 
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Astrocytes were removed from the flasks by incubation with 0.25% trypsin (type 
II-S; Sigma-Aldrich, St Louis, MO) and 0.04% EDTA (Sigma) and plated onto 
poly-L-lysine-coated six-well plates or coverslips in medium supplemented with 
10% FBS. Cells were plated at 15,000 cells/cm2 for immunocytochemistry and 
at 30,000 cells /cm2 for gene expression or protein assays. 
 
Cell treatments 
One day after seeding, culture medium was changed using serum free medium 
and the cells were treated for 24 or 72h with vehicle or IGF-I (50 or 100 nM), 
and in a second experiment the cells were treated for 24 or 72h with RAd-IGF-I, 
RAd-TK/GFP or medium alone (uninfected control cells). The efficacy of 
infection, assessed with the RAd-TK/GFP vector, was approximately 60% of the 
cells in the culture. Some cultures were incubated with lipopolysaccharide (LPS, 
from Escherichia coli 026:B6, Sigma; 500 ng/ml) to induce an inflammatory 
response [30]. LPS was added for 1h to determine NFκB subcellular 
localization and for 5 h to assess IGF-I receptor and IGF binding proteins by 
western blotting, and interleukin 6 (IL6), tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β) and toll-like receptor 4 (TLR4) mRNA levels by 
quantitative real-time polymerase chain reaction. In some experiments, 
astrocytes were incubated with the IGF-I receptor tyrosine kinase inhibitor 
picropodophyllin (PPP, Calbiochem, 100 ng/ml) or vehicle. 
 
IGF-I assay 
IGF-I was extracted from supernatants by acid–ethanol cryoprecipitation after 
incubation for 24 h with RAd-TK/GFP, RAd-IGF-I or medium alone. IGF-I levels 
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were assessed by radioimmunoassay as previously described [24] using 
antibody UB2-495 (distributed by A. F. Parlow, NHPP, NIDDK). Recombinant 
human IGF-I (Cell Sciences Inc., Canton, MA, USA) was used as tracer and 
unlabeled ligand. 
 
Analysis of gene expression by quantitative real-time polymerase chain 
reaction (q-PCR) 
Interleukin 6 (IL6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and 
toll-like receptor 4 (TLR4) mRNA levels were assessed by quantitative real-time 
polymerase chain reaction. Cells were lysed and total RNA was extracted using 
an illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, Buckinghamshire, 
UK). First strand cDNA was prepared from RNA using an RevertAidTM H Minus 
First Strand cDNA Synthesis Kit (MBI Fermentas, Bath, UK) following the 
manufacturer’s instructions. After reverse transcription (RT), the cDNA was 
diluted 1:4 and 5 µl were amplified by real-time PCR in 20 µl using SYBR Green 
master mix or TaqMan Universal PCR Master Mix (Applied Biosystems, AB, 
Foster City, CA) in a ABI Prism 7500 Sequence Detector (AB), with 
conventional AB cycling parameters (40 cycles of 95ºC, 15 s; 60ºC, 1 min). 
Primer sequences were designed using Primer Express (AB) and were as 
follows: for IL6, forward, 5´-GAAACCGCTATGAAGTTCCTCTCTG-3´ and 
reverse, 5´-TGTTGGGAGTGGTATCCTCTGTGA-3´; for TNF-α, forward 5´-
GAAAAGCAAGCAGCCAACCA-3´ and reverse, 5´-
CGGATCATGCTTTCTGTGCTC-3´; for IL-1β, forward 5´- 
CGACAAAATACCTGTGGCCT-3´ and reverse, 5´-
TTCTTTGGGTATTGCTTGGG-3´; and for TLR4, forward 5´-
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GGCTCCTGGCTAGGACTCTGA-3´ and reverse, 5´-
TCTGATCCATGCATTGGTAGGT-3´. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was selected as control housekeeping gene. GADPH 
TaqMan probes and primers were the Assay-on-Demand gene expression 
products (AB). After amplification, a denaturing curve was performed to ensure 
the presence of unique amplification products. All reactions were performed in 
triplicate. IL6, TNF-α, IL-1β and TLR4 gene expressions were normalized to 
GAPDH. 
 
Western blotting 
For western blotting analysis, medium and the cells were homogenized in 200 
µl of lysis buffer (150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 1 
mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml phenylmethylsulfonyl fluoride). 
Protein concentrations were determined using a Bio-Rad protein assay (Bio-
Rad Laboratories, Hercules, CA). Electrophoresis of 25-µg protein extracts was 
performed on a 10% acrylamide SDS-PAGE gel and immunoblotted onto 
nitrocelulose membranes. Membranes were incubated for 1 h in TBST (10 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 0.1% Tween-20) containing 5% wt/vol nonfat 
dry milk, and then incubated overnight with the primary antibodies. The 
following antibodies were used: anti-insulin-like growth factor-binding protein-2 
(IGFBP-2; Millipore Iberica, Madrid, Spain; diluted 1/2000), anti-IGFBP-3 (H-98; 
Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1/1000) and anti-IGF-I 
receptor-β (IGF-IRβ; C-20, Santa Cruz Biotechnology, Santa Cruz, CA; 1/1000). 
Immunoreactivity was detected with horseradish peroxidase-conjugated goat 
anti-rabbit or anti-mouse antibodies (Jackson ImmunoResearch Europe, 
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Newmarket, Suffolk, UK; Diluted 1:10000) and enhanced chemiluminescence 
(Amersham Pharmacia Biotech, Essex, UK). Band intensities were quantified 
using Quantity One 1-D Analysis Software (Bio-Rad Laboratories, Inc., 
Hercules, CA). 
 
Immunocytochemistry 
Subcellular distribution of NFκB (p65) was assessed by immunocytochemistry 
after incubation for 24 h with RAd-IGF-I or RAd-TK/GFP and for 1 h with LPS or 
vehicle. Cells were fixed for 15 min at room temperature in 4% 
paraformaldehyde, permeabilized for 15 min with 0.3% Triton X-100 in PBS and 
incubated for 15 min with 10% normal goat serum in PBS, to block unspecific 
binding of the secondary antibody. Cells were then incubated for 1 h with anti-
NFκB (p65) mouse monoclonal antibody (BD Biosciences, diluted 1:50 in PBS 
with 1% BSA). After washing in PBS, cells were incubated with goat anti-mouse 
Alexa-fluor 594 (Invitrogen, diluted 1:1,000). Cell nuclei were stained with DAPI. 
 
Statistical analysis  
Statistical significance was assessed by one-way or two-way analysis of 
variance (ANOVA) followed by the Bonferroni post hoc test using GraphPad 
Prism 5 (GraphPad Software, San Diego, CA) or by Student’s t-test when only 
two groups were compared. A probability of P < 0.05 was adopted for statistical 
significance. Data shown in the figures are the results of four independent 
experiments. Data are represented as mean ± SEM. 
 
Results 
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IGF-I increases the expression of IL6, IL-1β and TNF-α and decreases the 
expression of toll-like receptor 4 (TLR4) in astrocytes under basal 
conditions 
mRNA levels of IL6, IL-1β and TNF-α were assessed in astrocytes 24 h after 
the addition of IGF-I (50 and 100 nM) to the cultures. IGF-I, at a concentration 
of 50 nM, resulted in a significant increase in mRNA levels for IL6, IL-1β and 
TNF-α compared to astrocytes treated only with vehicle (Fig. 2). In contrast, 100 
nM IGF-I did not significantly affect IL6, IL-1β and TNF-α mRNA levels (Fig. 2). 
The increase in IL-1β mRNA levels was still detected 72 h after addition of 50 
nM IGF-I to the cultures (Fig. 2). However, levels of IL6 and TNF-α were not 
significantly different between astrocytes treated with IGF-I or vehicle, 72 h after 
addition of IGF-I (Fig. 2).  
 
TLR4 mRNA levels were significantly decreased in cultures treated with IGF-I at 
either 50 nM or 100 nM, compared to cultures treated with vehicle. The effect of 
IGF-I on TLR4 levels was still detected 72 h after treatment (Fig. 2).  
 
IGF-I exerts an anti-inflammatory action on LPS-treated astrocytes 
To determine whether IGF-I affects the response of astrocytes to a 
proinflammatory challenge, we first assessed mRNA levels of IL6, TNF-α, IL-1β 
and TLR4 in primary astrocyte cultures incubated with LPS (500 ng/ml) or 
vehicle. Treatment with LPS resulted in a marked increase in mRNA levels of 
IL6, IL-1β and TNF-α (Fig. 3). In contrast, TLR4 mRNA levels were not affected 
by LPS (Fig. 3).  
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For LPS-treated astrocytes, mRNA levels of IL6, IL-1β and TLR4 were 
significantly decreased 24 h after administration of 50 or 100 nM IGF-I in 
comparison to cultures treated with LPS alone (Fig. 4). mRNA levels of IL6, IL-
1β and TLR4 returned to control levels 72 h after addition of 50 nM IGF-I to the 
cultures (Fig. 4).  
 
RAd-IGF-I increases IGF-I levels in astrocyte cultures 
Having established the effects of exogenous application of IGF-I to astrocytes 
on IL6, IL-1β, TNF-α and TLR4 mRNA levels under basal and LPS-stimulated 
conditions, we investigated whether similar effects could be obtained by 
increasing endogenous expression of IGF-I in these cells using an adenoviral 
vector. To assess the efficacy of IGF-I gene transfer, IGF-I levels were 
assessed in the culture medium after incubation of the astrocytes for 24 h with 
RAd-IGF-I, RAd-TK/GFP, or medium alone (uninfected cells; Fig. 5). IGF-I 
levels were significantly higher in the medium of astrocytes incubated with RAd-
IGF-I compared to that of astrocytes incubated with RAd-TK/GFP or with 
medium alone (Fig. 5). In contrast IGF-I receptor levels and IGFBP2 levels were 
not significantly different in astrocytes incubated for 24 h with RAd-IGF-I, RAd-
TK/GFP, or medium alone (data not shown). IGFBP3 was undetectable in the 
cultures. 
 
RAd-IGF-I increases expression of IL6 and IL-1β and decreases 
expression of TLR4 under basal conditions 
IL6 and IL-1β mRNA levels in astrocytes were significantly increased 24 h after 
incubation of cultures with RAd-IGF-I, compared to those of uninfected 
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astrocytes or to astrocytes treated with RAd-TK/GFP (Fig. 6). In contrast, 72 h 
after incubation of the cultures with RAd-TK/GFP, astrocytes showed a 
significant increase in mRNA levels of IL6 and IL-1β, compared to uninfected 
astrocytes or to astrocytes treated with RAd-IGF-I (Fig. 6). IL6 and IL-1β mRNA 
levels 72 h after incubation with RAd-IGF-I were not significantly different from 
those in uninfected astrocytes (Fig. 6). TNF-α mRNA levels were increased 72 h 
after incubation with RAd-IGF-I. TLR4 mRNA levels were significantly 
decreased 24 h after incubation of the cultures with RAd-IGF-I, compared to 
astrocytes treated with RAd-TK/GFP (Fig. 6). 
 
RAd-IGF-I exerts an anti-inflammatory action on LPS-treated astrocytes 
After LPS treatment, astrocytes incubated with RAd-IGF-I showed a significant 
decrease in mRNA levels for IL6, IL-1β and TNF-α compared to astrocytes 
incubated with RAd-TK/GFP (Fig. 7). In addition, IL6 and IL-1β mRNA levels 
were significantly decreased in cultures incubated with RAd-IGF-I compared to 
uninfected cultures. In LPS-treated astrocytes, TLR4 mRNA levels were 
significantly decreased in cultures incubated for 24 h or 72 h with RAd-IGF-I 
compared to astrocytes treated with RAd-TK/GFP. In addition, TLR4 mRNA 
levels were significantly decreased in astrocytes incubated with RAd-IGF-I for 
24h compared to uninfected astrocytes. 
 
Role of IGF-I receptor in the effects of RAd-IGF-I 
To determine whether the effects of RAd-IGF-I on IL6, IL-1β, TNF-α and TLR4 
mRNA levels are mediated by IGF-I receptor, astrocyte cultures were treated 
with the IGF-I receptor antagonist cyclolignan picropodophyllin (PPP). As shown 
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in figure 8, PPP did not block the effect of RAd-IGF-I on IL6 mRNA levels under 
basal, un-challenged conditions (Fig. 8A). In fact, PPP treatment increased IL6 
mRNA abundance in cells infected with the Rad-IGF-I construct or the control 
construct. In contrast, PPP blocked the increase in IL-1β mRNA levels induced 
by RAd-IGF-I under basal conditions (Fig. 8C). PPP also resulted in an increase 
in TNF-α and TLR4 mRNA levels in cultures treated with RAd-IGF-I (Fig. 8 
E,G), preventing the decrease in TLR4 mRNA levels induced by RAd-IGF-I 
under basal conditions (Fig. 8G). 
 
In astrocytes treated with LPS, the effects of RAd-IGF-I on IL6, IL-1β, TNF-α 
and TLR4 mRNA levels were reverted by incubating the cultures for 5 h with 
PPP (Fig. 8B,D,F,H). In addition PPP increased mRNA levels of IL6 and IL-1β 
in LPS-treated astrocytes incubated with RAd-TK/GFP or RAd-IGF-I (Fig. 
8B,D).  
 
RAd-IGF-I prevents LPS-induced nuclear translocation of the NFκB p65 
subunit 
Since activation of TLR4 results in nuclear translocation of the NFκB p65 
subunit, we assessed whether RAd-IGF-I affects p65 subcellular distribution in 
astrocytes. The incubation of astrocytes with RAd-TK/GFP and LPS resulted in 
a significant increase in p65 immunoreactivity in the cell nucleus compared to 
astrocytes incubated with RAd-TK/GFP alone. In contrast, p65 nuclear 
immunoreactivity was not increased by LPS in astrocytes incubated with RAd-
IGF-I (Fig. 9). Therefore, RAd-IGF-I prevented LPS-induced p65 nuclear 
translocation.  
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Discussion 
The findings of the present study indicate that IGF-I increases the expression of 
IL6, IL-1β and TNF-α in cultured astrocytes under basal conditions. In contrast, 
IGF-I decreases expression of IL6 and IL-1β in cultured astrocytes submitted to 
a proinflammatory challenge by treatment with LPS. Under basal conditions, the 
effects of IGF-I on expression of IL6, IL-1β and TNF-α were dependent on IGF-I 
dose, promoting these cytokine expressions at the lower dose. When 
challenged with LPS, however, IGF-I at both dosages exerted similar inhibitory 
effects on the expression of IL6 and IL-1β. 
 
The increases in IL6, IL-1β and TNF-α mRNA levels detected in astrocytes after 
treatment with IGF-I under basal conditions does not necessarily imply a 
proinflammatory action of IGF-I. Cytokines such as IL6, IL-1β and TNF-α have 
different physiological functions, including regulation of neuronal development, 
ionic homeostasis, neuropeptide release and synaptic plasticity [31-34]. 
Therefore, the observed increases in IL6, IL-1β and TNF-α levels under basal 
conditions may represent a physiological action of IGF-I. In addition, IGF-I 
reduced expression of TLR4 in both the presence and absence of LPS. TLR4 is 
a member of the IL-1receptor/TLR superfamily that is expressed by astrocytes 
and that is required for an LPS-induced inflammatory response [35-38]. 
Therefore the observed decrease in TLR4 expression by IGF-I under basal 
conditions and after LPS proinflammatory challenge may contribute to a 
reduced capacity of astrocytes to be activated by proinflammatory molecules 
such as LPS. Indeed, IGF-I reduced the effects of LPS on mRNA levels of IL6, 
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and IL-1β in astrocytes, in agreement with previous findings showing that IGF-I 
down-regulates cytokine expression induced by LPS in adult mouse brain [39].  
 
Having established that exogenous IGF-I regulates the expressions of IL6, IL-
1β, TNF-α and TLR4 in astrocytes, we then assessed whether an increase in 
endogenous production of IGF-I by astrocytes might also affect expression of 
these molecules. The findings of the present study indicate that a recombinant 
adenoviral vector harboring the gene for rat IGF-I (RAd-IGF-I) is able to 
increase the production of IGF-I in astrocytes, without affecting IGFBP2 or IGF-I 
receptor levels.  Under basal conditions, RAd-IGF-I resulted in an effect similar 
to that of IGF-I, increasing the expression of IL6 and IL-1β and decreasing the 
expression of TLR4. Adenoviral vector infection per se also had an effect, since 
mRNA levels of IL6 and IL-1β were increased in astrocytes 72h after incubation 
with control vector, RAd-TK/GFP. In addition, TNF-α mRNA levels were 
increased in astrocytes incubated for 72h with RAd-IGF-I. However, no increase 
for IL6 or IL-1β was detected at 72 h in astrocytes infected with RAd-IGF-I, 
suggesting that IGF-I is compensating for some of the proinflammatory actions 
of the adenoviral vector. Indeed, RAd-IGF-I exerted a clear anti-inflammatory 
action on LPS-treated astrocytes, decreasing the mRNA levels of IL6, IL-1β, 
TNF-α and TLR4. Therefore, RAd-IGF-I imitated the effects of IGF-I on LPS-
stimulated astrocytes. These findings demonstrate efficacy of IGF-I gene 
therapy in reducing the response of astrocytes to an inflammatory challenge. 
However, as was observed for exogenous IGF-I, the anti-inflammatory action of 
IGF-I gene therapy was transient, since RAd-IGF-I did not significantly affect 
levels of IL6, IL-1β, or TNF-α in cultures incubated with the viral vector for 72 h.  
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Our data suggest that RAd-IGF-I, like IGF-I, reduces the effects of LPS on 
astrocytes by decreasing the expression of TLR4. Activation of TLR4 results in 
translocation of the NFκB p65 subunit to the cell nucleus and consequent 
activation of NFκB-mediated transcription of proinflammatory cytokines and 
chemokines [40-44]. In agreement with the effect of RAd-IGF-I on TLR4 
expression, and with the results of a previous study on the effect of IGF-I on 
astrocytes [18], IGF-I gene therapy prevented LPS-induced translocation of the 
NFκB p65 subunit to the cell nucleus. This suggests that RAd-IGF-I exerts, at 
least in part, its anti-inflammatory action by downregulation of TLR4 and 
subsequent inhibition of NFκB activity.  
 
The anti-inflammatory action of RAd-IGF-I in LPS-stimulated astrocytes may be 
mediated by IGF-I receptor activation, since it was prevented by incubation of 
astrocytes with cyclolignan picropodophyllin (PPP), an inhibitor of the IGF-I 
receptor tyrosine phosphorylation [45-47]. However, PPP treatment per se 
increased IL6 mRNA levels in cells infected with Rad-IGF-I construct or control 
construct under basal conditions, and increased mRNA levels of IL6 and IL-1β 
in LPS-treated astrocytes incubated with RAd-TK/GFP or RAd-IGF-I. These 
actions of PPP cannot be explained simply by IGF-I receptor inhibition, 
suggesting that PPP may have other effects under the experimental conditions 
used. 
 
Conclusion 
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The results of the present study indicate that IGF-I and IGF-I gene therapy are 
able to reduce inflammatory reactions in glial cells exposed to LPS. This action 
of IGF-I and IGF-I gene therapy may be relevant for control of reactive gliosis 
under chronic neurodegenerative conditions, where the glial inflammatory 
response is thought to have a negative impact on neuronal function and 
survival. 
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Figure legends 
 
Figure 1. Schematic representation of the construction of the RAd-IGF-I 
and RAd-TK/GFP adenoviral vectors. 
PmCMV, mouse cytomegalovirus promoter; IGF-I, cDNA for rat IGF-1; TK/GFP, 
hybrid DNA sequence encoding the fusion protein TK/GFP; ITR, inverted 
terminal repeat; ∆E1 and ∆E3, deletions in the AD5 genome; SV40, simian 
virus 40 polyadenylation signal; Ψ, packaging signal. 
 
Figure 2. IGF-I increases the expression of IL6, IL-1β and TNF-α and 
decreases the expression of TLR4 in astrocytes under basal conditions. 
mRNA levels of IL6 (A,B), IL-1β (C,D), TNF-α (E,F) and TLR4 (G,H) in 
astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of IGF-I (50 or 
100 nM) or vehicle to the cultures. Data are presented as mean ± SEM and are 
expressed as percentage of control (vehicle) values. *,**,***, Significant 
differences (* P < 0.05; **P < 0.01; ***P<0.001) in comparison to the values of 
cultures treated with vehicle only. §§, §§§, Significant differences (§§P < 0.01; 
§§§P<0.001) between 50 nM and 100 nM IGF-I. 
 
Figure 3. LPS increases expression of IL6, IL-1β, TNF-α and TLR4 in 
astrocytes. 
mRNA levels of IL6 (A), IL-1β (B), TNF-α (C) and TLR4 (D) in astrocytes treated 
for 5 h with LPS (500 ng/ml) or vehicle only. Data are presented as mean ± 
SEM and are expressed as percentage of control (vehicle) values. **,***, 
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Significant differences (**P < 0.01; ***P<0.001) in comparison to the values of 
cultures treated with vehicle. 
 
Figure 4. IGF-I decreases the inflammatory response of astrocytes 
exposed to LPS. 
mRNA levels of IL6 (A,B), IL-1β (C,D), TNF-α (E,F) and TLR4 (G,H) in 
astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of IGF-I (50 or 
100 nM) or vehicle only and treated for the last 5 h with LPS. Data are 
presented as mean ± SEM and are expressed as percentage of control 
(vehicle+LPS) values. *,***, Significant differences (* P < 0.05; ***P<0.001) in 
comparison to the values of cultures treated with vehicle+LPS. 
 
Figure 5. RAd-IGF-I increases release of IGF-I by astrocytes.  
Levels of IGF-I in the culture medium of astrocytes incubated for 24 h with 
medium alone (uninfected cells), RAd-TK/GFP or RAd-IGF-I. Total IGF-I was 
assayed in supernatants and the peptide concentration referred to the original 
volume of medium per well. Bars on columns represent mean ± SEM, (n=4). ***, 
Significant difference (P < 0.001) versus the values of the other two 
experimental groups. 
 
Figure 6. RAd-IGF-I increases the expression of IL6 and IL-1β and 
decreases the expression of TLR4 in astrocytes under basal conditions. 
mRNA levels of IL6 (A,B), IL-1β (C,D), TNF-α (E,F) and TLR4 (G,H) in 
astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of RAd-TK/GFP 
or RAd-IGF-I to the cultures. Data are presented as mean ± SEM and are 
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expressed as percentage of control (uninfected cells) values. *,**,***, Significant 
differences (* P < 0.05; **P < 0.01; ***P<0.001) in comparison to the values of 
uninfected cells. §, §§, §§§, Significant differences (§P<0.05; §§P < 0.01***; 
§§§P<0.001) between RAd-TK/GFP and RAd-IGF-I. 
 
Figure 7. RAd-IGF-I decreases the expression of proinflammatory 
molecules in LPS-stimulated astrocytes. 
mRNA levels of IL6 (A,B), IL-1β (C,D), TNF-α (E,F) and TLR4 (G,H) in 
astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of RAd-TK/GFP 
or RAd-IGF-I and treated for the last 5 h with LPS. Data are presented as mean 
± SEM and are expressed as percentage of control (uninfected cells treated 
with LPS) values. *,**, Significant differences (* P < 0.05; **P < 0.01) in 
comparison to the values of uninfected cells. §, §§, Significant differences (§P < 
0.05; §§P < 0.01) between RAd-TK/GFP and RAd-IGF-I. 
 
Figure 8. Effects of an IGF-I receptor antagonist on uninfected astrocytes 
and on astrocytes incubated with the adenoviral vectors. 
mRNA levels of IL6 (A,B), IL-1β (C,D), TNF-α (E,F) and TLR4 (G,H) in 
astrocytes 24 h after the addition of RAd-TK/GFP or RAd-IGF-I and treated for 
the last 5 h with the IGF-I receptor tyrosine kinase inhibitor PPP or its vehicle in 
the absence (A,C,E,G) or the presence of LPS (B,D,F,H). Data are presented 
as mean ± SEM and are expressed as percentage of control (uninfected cells 
treated with the vehicle for PPP) values. *,**,***, Significant differences (* P < 
0.05; **P < 0.01; ***P < 0.001) in comparison to control values. +,++,+++, 
Significant differences between PPP and its vehicle.  
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Figure 9. RAd-IGF-I prevents LPS-induced nuclear translocation of the 
NFκB p65 subunit. 
Astrocyte cultures were treated for 24 h with RAd-IGF-I and for 1 h with LPS, 
and the level of p65 immunoreactivity in nucleus and cytoplasm was 
determined. A-D, Representative examples of p65 immunostaining in astrocytes 
incubated with RAd-TK/GFP (A), RAd-TK/GFP+LPS (B), RAd-IGF-I (C) and 
RAd-IGF-I+LPS (D), Scale bar, 40 µm. E, Results of densitometric analysis of 
p65 immunoreactivity expressed as a ratio between immunoreactivity in the cell 
nucleus and the cell cytoplasm. Data are presented as mean ± SEM and are 
expressed as percentage of control (uninfected cells treated with vehicle) 
values. ++,+++ Significant differences (++P < 0.01, +++P < 0.001) between LPS and 
its vehicle. *, Significant difference (*P < 0.05) versus uninfected+LPS and 
versus RAd-TK/GFP + LPS values. 
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